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Abstract
Background: Research has identified high failure rates of peripheral intravenous catheter (PIVC) and varied flushing
practices.
Methods: This is a single-centre, pilot, non-masked, factorial randomised controlled trial. Participants were adults,
with a PIVC of expected use ≥24 hours (n = 160), admitted to general medical or surgical wards of a tertiary referral
hospital in Queensland (Australia). Patients were randomly allocated to one of four flush groups using manually
prepared syringes and 0.9 % sodium chloride: 10 mL or 3 mL flush, every 24 or 6 hours. The primary endpoint was
PIVC failure, a composite measure of occlusion, infiltration, accidental dislodgement and phlebitis.
Results: PIVC average dwell was 3.1 days. PIVC failure rates per 1000 hours were not significantly different for the
volume intervention (4.84 [3 mL] versus 7.44 [10 mL], p = 0.06, log-rank). PIVC failure rates per 1000 hours were also
not significantly different for the frequency intervention (5.06 [24 hour] versus 7.34 [6 hour], p = 0.05, log-rank). Cox
proportional hazard regression found neither the flushing nor frequency intervention, or their interaction (p = 0.21)
to be significantly associated with PIVC failure. However, female gender (hazard ratio [HR] 2.2 [1.3–3.6], p < 0.01),
insertion in hand/posterior wrist (HR 1.7 [1.0–2.7], p < 0.05) and the rate per day of PIVC access (combined flushes
and medication pushes) (HR 1.2 [1.1–1.4], p < 0.01) significantly predicted PIVC failure.
Conclusion: Neither increased flushing volume nor frequency significantly altered the risk of PIVC failure. Female
gender, hand/posterior wrist placement and episodes of access (flushes and medication) may be more important.
Larger, definitive trials are feasible and required.
Trial registration: Australian and New Zealand Clinical Trials Registry: ACTRN12615000025538. Registered on 19
January 2015.
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Background
Peripheral intravenous catheters (PIVCs) are the most
commonly used invasive devices in hospitals; they are re-
lied upon for therapy across nearly all medical and surgi-
cal specialties [1–3]. Yet failure prior to completion of
therapy occurs in up to 69 % of patients [4–12]. This
may be due to a range of complications, which can be
mechanical, vascular or infectious. Mechanical complica-
tions include occlusion, infiltration and dislodgement.
Vascular complications include venous thrombotic oc-
clusion and phlebitis (irritation or inflammation of the
vessel wall). Infectious complications may be bacterial or
fungal, and local or systemic bloodstream infections.
Complications lead to device failure and device replace-
ment, which results in interrupted therapy, pain associ-
ated with resiting and increased health care costs for
resources and staff time [13]. Bloodstream infections
prolong hospitalisation and increase treatment costs and
mortality [14, 15].
The interactions believed to cause mechanical and vas-
cular complications are based on the following theoret-
ical understandings. A fibrin coating forms within the
PIVC lumen and catheter tip within 24 hours of place-
ment. Fibrin can form the basis for thrombus develop-
ment, which as well as being a nidus for infection, can
occlude the PIVC lumen and even the vessel [16]. Simi-
larly, inappropriate concentrations of injected/infused
solutions, or incompatible mixtures, can cause fluids or
medications to precipitate within the catheter lumen
and may obstruct the catheter [17].
Current practice recommendations are to flush PIVCs
before and after each medication administration, and at
regular intervals when PIVCs are not in use [15, 18, 19].
The theoretical purpose of flushing is to maintain cath-
eter patency by preventing internal luminal occlusion,
reducing build-up of blood and other products on the
PIVC internal surface and preventing interaction of in-
compatible fluids/medicines [18, 19].
Flushing is a historical practice, based more on derived
scientific principles and tradition than on randomised
controlled trials (RCTs), and current flushing practices
vary widely [20, 21]. This has implications for costs and
workload [13]. A large survey of flushing practices re-
vealed a high level of policy awareness (72 %) but varied
levels of adherence. Approximately half of respondents
stated that there was no medical order or documenta-
tion for the flush. Twenty-five percent of respondents
used a syringe smaller than the required 10 mL. Use of
prefilled syringes was limited to 10 %. The frequency of
flushing varied widely from 4th hourly to never, with the
most common responses being pro re nata (23 %) or 6th
hourly (23 %) [20].
There are no RCTs in adult patients comparing different
flushing volumes and frequencies that are in common
practice today. A single-site paediatric RCT found no
significant difference in overall PIVC failure with varied
flushing frequencies [22]. Large RCTs in varied patient
populations are urgently needed to identify the ideal flush-
ing methods including frequency and volume. This would
inform practice to [1–3] prevent PIVC failure, thus pre-
venting painful complications and reinsertions, and reduce
organisational costs [13]. This pilot study aimed to test
the effect of both volume and frequency on PIVC failure,
in preparation for future large trials.
Methods
The study was a four-arm, 2 × 2 factorial design RCT
comparing the effectiveness of different flushing fre-
quencies (more versus less) and volumes (high versus
low) in maintaining the patency of PIVCs. A factorial de-
sign enables more than one clinical question to be tested
from a single RCT [23]. In addition to testing the feasi-
bility of conducting a larger trial, our hypotheses were
that both increased flushing volume and frequency
would decrease PIVC failure.
Study interventions
Patients were allocated to one of the four following study
arms:
1. High volume, high frequency (10 mL every 6 hours)
2. High volume, low frequency (10 mL every 24 hours)
3. Low volume, high frequency (3 mL every 6 hours)
4. Low volume, low frequency (3 mL every 24 hours)
The volume and frequency parameters were derived
from reported practice in a large cross-sectional survey,
guidelines and literature [20]. Flushes were 0.9 % sodium
chloride using syringes that were manually prepared by
ward nursing staff (prefilled syringes were not used).
Colour coded stickers indicating the flush prescription
were placed in the regular order section of the pa-
tient’s medication chart. This order was in addition to
the recommended practice of 5–10 mL pre- and post-
medication flushes with 0.9 % sodium chloride. Con-
firmation of intravenous (IV) flush as per protocol was by
the nursing signature against prescription in medication
chart.
Insertion and care of PIVCs
Forty-five percent of all PIVCs were inserted by special-
ist nursing IV inserters. The remainder were inserted by
clinical nursing or medical staff. The skin preparation
used was chlorhexidine 2 % with isopropyl alcohol 70 %
swabs (SOLU-IVMC/TM 3 M St Paul, MN, USA). BD
Insyte™ Autoguard™ BC catheters were used with BD
Connecta™ extension tubing and CareFusion SmartSite®
needleless connectors (BD Medical, Franklin Lakes,
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NJ, USA). PIVCs were secured with standard simple
polyurethane dressings. Nursing (not the research or
IV team) and medical staff provided follow-up care.
Catheter sites were labelled to identify study inclusion.
PIVCs were replaced on clinical indication as per hospital
policy, although occasionally some medical staff still re-
quested routine replacement. The Research Nurses (RNs)
visited patients daily to visually inspect the PIVC, re-
mind staff of research protocol, gather data collection
sheets (until two days after removal of the PIVC) and
assess for outcome measures and adverse events.
Other data were obtained by the RNs from patient
charts, notes, computerised administration and path-
ology systems.
Outcome measures
This pilot study collected outcomes to establish feasibility
of the protocol and processes. Feasibility data outcomes
included the success of screening and recruitment strat-
egies; ease of data collection processes and technology;
and resources and research staff time.
The primary endpoint for both the volume and fre-
quency hypotheses was PIVC failure, a composite of any
unplanned PIVC removal prior to completion of therapy.
This included: occlusion (PIVC will not infuse, or leakage
occurs when fluid infused), infiltration (leakage of fluid
into surrounding tissues), accidental dislodgement and
phlebitis (score of 2 or more of pain/tenderness, redness,
swelling, purulence and/or a palpable cord). A secondary
outcome was infection (laboratory-confirmed local or
bloodstream infection) [24, 25].
Setting and sample
The trial was undertaken in surgical and medical wards
at a large tertiary metropolitan hospital in Brisbane,
Australia, where 160 patients were recruited over four
months. This number is adequate in pilot trials to repre-
sent the target population of larger RCTs for the purposes
of assessing feasibility [26].
Potentially eligible patients were those aged 18 years or
over, with a PIVC that had been inserted within 24 hours
of recruitment, or was about to be inserted and expected
to remain for >24 hours, and who gave written informed
consent. Exclusion criteria included: non-English-speaking
patients without an interpreter and patients receiving
continuous IV therapy. Only one PIVC per patient was
studied. The study received ethics committee approval
from the Royal Brisbane and Women’s Hospital Human
Research Ethics Committee (HREC/13/QRBW/420) and
Griffith University Human Research Ethics Committee
(NRS/12/14/HREC), and the trial was registered with the
Australian and New Zealand Clinical Trials Registry:
ACTRN12615000025538.
Recruitment, randomisation, allocation concealment and
blinding
Staff education about study aims and processes was con-
ducted prior to commencement of study on all wards.
An RN screened patients daily, gained informed consent,
performed randomisation and liaised with the ward
nursing and medical teams. Eligible patients were invited
to participate in the study and written informed consent
gained. Randomisation (simple) was obtained via a centra-
lised web-based service (https://www151.griffith.edu.au)
and was generated in a 1:1:1:1 ratio for the four study
groups. Allocation concealment was maintained until each
patient’s study entry. A Project Manager undertook regu-
lar quality checks to ensure allocation integrity and data
quality. Intravenous flush orders were not amenable to
blinding of patients, clinical staff or RNs.
Data collection
The RNs collected and entered data in the clinical areas
using preformatted case report forms and then entered
the data into a purpose-built computer database (Research
Electronic Data Capture, Vanderbilt University). All data
were de-identified at this point and only identifiable
within the database by specific study number. Patient
characteristics collected by RNs at baseline included: age,
sex, estimated weight category, diagnostic group, domin-
ant limb, vein quality, skin integrity, co-morbidities, length
of stay, immunodeficiency, current infection and intraven-
ous therapy (including antimicrobial). PIVC characteristics
collected were: device type, insertion site, PIVC gauge,
side of insertion, clinical area/ward, inserter discipline, ini-
tial/subsequent PIVC and the addition of extension tubing
and injection ports. The RNs visually inspected PIVCs
daily and assessed for phlebitis. After PIVC removal, the
following data were collected: reason for PIVC removal,
dwell time, phlebitis with 48 hours of removal, hospital
length of stay and hospital mortality. The number of PIVC
accesses to administer medication/flushes was recorded
from the patient’s medication charts. In the case of any
suspected blood stream infections, clinical staff ordered
blood and PIVC cultures from patients suspected as per
usual practice and RNs accessed the results.
Data analysis
Data cleaning and analyses were performed in Stata
(14.1, StataCorp, College Station, TX, USA). An intention-
to-treat analysis framework was used. Mean values and
standard deviations were reported for normally distributed
data; median values and interquartile range were reported
otherwise. As a pilot study, we tested our statistical com-
parison methods, but did not expect to find statistical dif-
ferences. Incidence rates of PIVC failure per 1000 PIVC
hours (95 % confidence intervals [CIs] were calculated,
and Kaplan-Meier curves generated. The null hypotheses
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of no differences in PIVC survival with increased volume
or increased frequency were tested with the log-rank test
of equality. Cox proportional hazard models (univariable
and multivariable) were fitted and hazard ratios (HRs) cal-
culated, including an interaction term between volume
and frequency. The interaction was confirmed with Alt-
man and Bland’s method (results not presented) [27].
Covariates were selected for the multivariable model
at p < 0.2 in the univariable model, and dropped if corre-
lated with another covariate (at ρ > 0.5 and p < 0.05). The
final multivariate model was built using manual stepwise
backward removal of covariates at p < 0.05 [27]. The pro-
portional hazards assumption was checked.
Results
Feasibility outcomes
One hundred and seventy-three patients were screened
for eligibility, with 160 recruited (Fig. 1). One hundred
percent of recruited patients were randomised, giving an
average of 40 patients per month. Staff on study wards
were cooperative and supportive of the trial. RNs spent
an average of 4 hours a day (Monday to Friday) recruit-
ing and data collecting for the trial. Only follow-up data
were collected on weekends for approximately 2 hours a
day when RNs covered for a range of studies. All partici-
pants received the allocated intervention with no proto-
col violations, and no patients were lost to follow-up.
Patients and PIVCs
At baseline, groups were similar in demographic and
clinical risk profiles (Table 1). PIVCs were used for an
average 3.1 (median: 2.70) days across all study groups
and total 11,911 PIVC hours were studied (Table 2). The
overall PIVC failure rate was 46 % or 6.13/1000 device
hours, with occlusion and phlebitis the most common
reasons for PIVC failure. No confirmed PIVC-related
Fig. 1 Participant flowchart
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infections occurred in any group. Two suspected PIVC
infections occurred; one patient had gram-negative ba-
cilli in both peripheral blood and urine, the second had
a blood culture with probable skin contaminant.
Primary endpoint
The incidence rate of PIVC failure in patients assigned
to 3 mL flushing was 4.8 per 1000 hours compared with
7.4 per 1000 hours in those assigned to 10 mL flushing
(p = 0.063, log-rank, Table 2 and Fig. 2). The incidence
rate of PIVC failure in patients assigned to 24 hour
flushing was 5.1 per 1000 hours compared with 7.3 per
1000 hours in those assigned to 6 hour flushing (p =
0.054, log-rank, Table 2 and Fig. 2). There was no signifi-
cant interaction between the two study interventions
(p = 0.21, Cox, Table 3); i.e. the results for comparison
of the two volumes were not affected by the frequency, and
the results for comparison between the two frequencies
Table 1 Patient and insertion characteristics at baseline (n = 160)
Characteristic Total (n = 160) Flush volume Flush frequency
3 mL (n = 80) 10 mL (n = 80) 24 h (n = 79) 6 h (n = 81)
Group size 160 (100) 80 (50) 80 (50) 79 (49) 81 (51)
Age (median, IQR) 63 (24) 63 (22) 64 (30) 63 (26) 64 (23)
Gender (male) 93 (58) 53 (66) 40 (50) 47 (59) 46 (57)
Overweight/obesea 70 (44) 33 (41) 37 (46) 33 (42) 37 (46)
Comorbidities (≥2) 110 (69) 51 (64) 59 (74) 57 (72) 53 (65)
Skin integrity (poor) 24 (15) 12 (15) 12 (15) 12 (15) 12 (15)
Infection (any type) 43 (27) 22 (28) 21 (26) 18 (23) 25 (31)
Antibiotic treatment 115 (72) 57 (71) 58 (72) 60 (76) 55 (68)
Frequency of IV txb:
- 0 15 (11) 10 (12) 5 (6) 8 (10) 7 (9)
- 1–2 times daily 23 (17) 10 (12) 13 (16) 14 (18) 9 (11)
- 3–4 times daily 71 (54) 35 (44) 36 (45) 37 (47) 34 (42)
- ≥5 times daily 23 (17) 13 (16) 10 (12) 8 (10) 15 (19)
Inserted in dominant arm 80 (52) 37 (47) 36 (49) 36 (48) 37 (47)
Insertion point:
- post. wrist 39 (24) 22 (28) 17 (21) 18 (23) 21 (26)
- hand 38 (24) 18 (22) 20 (25) 18 (23) 20 (25)
- post. u/l forearm 30 (19) 15 (19) 15 (19) 17 (22) 13 (16)
- ant. u/l forearm 29 (18) 15 (19) 14 (18) 14 (18) 15 (19)
- cub. fossa/ant. u arm 24 (15) 10 (12) 14 (18) 12 (15) 12 (15)
Vein quality (poor) 85 (53) 41 (51) 44 (55) 39 (49) 46 (57)
Insertion in wardc 118 (74) 59 (74) 59 (74) 59 (75) 59 (73)
Inserted by:
- IV nurse inserter 72 (45) 36 (45) 36 (45) 39 (49) 33 (41)
- any doctor 68 (43) 35 (44) 33 (41) 35 (44) 33 (41)
- any nurse/unknown 20 (13) 9 (11) 11 (14) 5 (6) 15 (19)
Multiple insertion attempts 32 (20) 15 (19) 17 (22) 17 (22) 15 (19)
Device sized:
- 22 gauge 76 (48) 37 (46) 39 (49) 35 (44) 41 (51)
- 20 gauge 67 (42) 33 (41) 34 (42) 35 (44) 32 (40)
Extension tubing 82 (51) 41 (51) 41 (51) 43 (54) 39 (48)
3-way tap 118 (74) 59 (74) 59 (74) 59 (75) 59 (73)
n (%) shown unless otherwise indicated post. posterior, ant. anterior, cub. cubital, mL millilitres, h hours, tx treatment, uupper, l lower
a Estimated
b Frequencies may not add up to group size due to missing/omitted values
c Versus all other
d Other categories omitted
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were also not affected by the volume. Univariable Cox re-
gression found estimates of effect for both the volume and
frequency interventions to be large but not statistically sig-
nificant (Table 3). Failure was increased with 10 mL (versus
3 mL) volume (HR 1.56, 95 % CI 0.97–2.50, p = 0.06), and
6 hour (versus 24 hour) flushing (HR 1.58, 95 % CI 0.99–
2.53, p = 0.06). On multivariable analysis, volume, fre-
quency and their interaction remained non-significant, but
female gender (HR 2.2, 95 % CI 1.3–3.6, p < 0.01), insertion
in hand/posterior wrist (HR 1.7, 95 % CI 1.0–2.7, p < 0.05)
and increased episodes rate per day (combined flushes and
medication pushes) (HR 1.2, 95 % CI 1.1–1.4, p < 0.01) sig-
nificantly predicted PIVC failure. Increasing the average
daily episode rate by one (e.g. from three to four episodes
per day) was associated with a 25 % increase in the relative
risk of failure.
Discussion
This pilot study was initiated in response to an un-
acceptably high PIVC failure rate in our organisation
and resultant high morbidity and costs [10, 12]. This is
one of the first RCTs to evaluate the impact of different
flushing volumes and frequencies on PIVC outcome.
Feasibility of a future large trial was indicated, with the
interventions acceptable to ward staff and feasible to
conduct in the clinical setting as demonstrated by the
protocol adherence and successful recruitment rate. Ini-
tial group comparisons suggested that higher frequency
and higher volume flushing were associated with in-
creased PIVC failure. This is counter-intuitive to current
practice, where it is believed more often and larger vol-
ume flushing equals less PIVC failure. However, univari-
able and multivariable regression showed that flushing
volume and frequency were not significantly associated
with failure. Retrospectively, the study power was 40 %
and 14 % for the volume and frequency hypotheses
respectively; larger, definitive trials would require 140
patients/group (volume), and 520 patients/group (fre-
quency) (90 % power, alpha 0.05, https://stat.ubc.ca/
~rollin/stats/ssize/).
Similar to our results, a single-site trial (n = 397) of
different flushing frequencies (3 mL twice daily versus
3 mL once daily) in Italy also found no significant differ-
ence in risk of PIVC failure (12.1 % versus 9.5 % p =
0.42) [22]. However, their sample was a select paediatric
population (receiving no infusion therapy or intravenous
antibiotics, and using prefilled flush syringes), quite dif-
ferent from our cohort. Additionally, their observed
overall proportion of failure (8.7 %) was very low
compared to other studies. This suggests that the use
of prefilled and/or pressure limiting syringe technology
needs to be explored to optimise flush and medication
administration.
PIVC failure was significantly associated with the in-
creasing episode rate of PIVC accesses per day. However,
medication type (i.e. drug or antibiotic classification)
was not a significant contributing factor to PIVC failure.
So if it is not the flush volume, frequency or medication
type that predicts failure, it may be the excessive injec-
tion pressure associated with manually prepared syringes
that damages the vessel intima, by direct pressure and/
or haemodilution activating the endothelium [17]. It
could also be the manual handling of the PIVC during
administration.
Our recent survey of flushing practices (n = 1178) re-
vealed 23 % of nurses/midwives used a 5 mL or 2 mL
syringe to deliver a flush, and almost all used manually
prepared flush syringes [20]. This implies a lack of ap-
preciation for the increase in pressure per square inch
associated with the properties of smaller size syringes.
The use of reduced pressure for flush delivery through a
syringe with a larger diameter such as the standard
Table 2 Device outcomes at removal
Outcome Total (n = 160) Flush volume Flush frequency
3 mL (n = 80) 10 mL (n = 80) 24 h (n = 79) 6 h (n = 81)
Device failure: 73 (46) 29 (36) 44 (55) 32 (41) 41 (51)
- occlusion or leaking 22 (14) 12 (15) 10 (12) 9 (11) 13 (16)
- infiltration 18 (11) 4 (5) 14 (18) 10 (13) 8 (10)
- phlebitis or too painful 22 (14) 7 (9) 15 (19) 8 (10) 14 (17)
- dislodgment 15 (9) 5 (6) 10 (12) 7 (9) 8 (10)
Device dwell time (days)a 2.70 (1.66–4.02) 2.23 (1.46–4.32) 2.73 (1.71–3.98) 2.83 (1.65–4.25) 2.26 (1.67–3.58)
Device-hours 11,911 5,998 5,914 6,327 5,584
Incidence rate (95 % CI)b 6.13 (4.87–7.71) 4.84 (3.36–6.96) 7.44 (5.54–10.0) 5.06 (3.58–7.15) 7.34 (5.41–9.97)
Log-rank test (p value) - 0.063 0.054
n (%) shown unless otherwise noted
CI confidence interval
a Median and inter-quartile range
b Per 1000 device-hours
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10 mL syringe is recommended to optimise flush out-
comes and minimise damage to the vein [17, 28, 29].
These recommendations are largely derived from physics
principles, and have not been tested in clinical trials. In
recent times, commercially prepared prefilled flush sy-
ringes have become available, which negate the potential
for operators to make an incorrect choice of a smaller
size syringe, since they are produced in diameters con-
sistent with a 10 mL syringe, but in 3, 5 and 10 mL
volumes.
Female gender was significantly associated with PIVC
failure (HR 2.2), consistent with a previous study where
females were significantly more at risk for both phlebitis
(HR 1.64, p < 0.001) and occlusion (HR 1.44, p < 0.001)
[30]. While gender is a non-modifiable factor, staff
should take this high risk factor into consideration for
best-practice insertion, monitoring and maintenance
regimens.
We also identified hand/wrist insertion as a significant
risk for PIVC failure (HR 1.7). Previous research con-
firmed insertion site as a predictor of PIVC failure.
Again, insertion in the hand compared to the forearm
had an HR of 1.47 (p < 0.001) for occlusion and an HR
of 2.45 (p < 0.001) for accidental removal in previous
work [30]. Other research has linked insertion site with
phlebitis [14, 31, 32]. PIVC insertion site is a variable
over which clinicians can exercise judgement and choice,
and they should therefore consider these risks in relation
Fig. 2 Kaplan-Meier survival from PIVC failure (n = 160) by a flushing volume (p = 0.063, log-rank) and b flushing frequency (p = 0.054, log-rank)
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to their insertion practice. Guideline site recommenda-
tions have recently been updated to preference the fore-
arm [18, 24, 33].
It is clear that the mechanisms of how IV flushing,
medication and fluid administration impact on PIVC
complications require further elucidation. The litera-
ture to date, including Schreiber and colleagues
(2015) [22] and this pilot study, have not identified
effective flushing regimens. There are few RCTs per-
formed on PIVC flushing, and this study provides
new, rigorous data that contribute to knowledge in
this area. More recently, clinically indicated replacement
has allowed catheters to be used for longer periods,
so trials such as this are needed to investigate how
improved maintenance can keep PIVCs functional over
time [34].
Table 3 Cox proportional hazards regression (n = 160)
Univariable Multivariable
HR (95 % CI) HR (95 % CI)
10 mL volume (referent: 3 mL) 1.56 (0.97–2.50)* f
6 hr frequency (referent = 24 h) 1.58 (0.99–2.53)* f
Interaction of volume and frequencya 0.54 (0.21–1.42) f
Age (one year increase) 1.00 (0.99,1.02) f
Gender (female) 1.90 (1.18,3.05)*** 2.17 (1.33,3.55)***
Weight (over/obese) 1.29 (0.81,2.05) f
Comorbidities (one category higher)b 1.03 (0.78,1.35) f
Insertion on dominant side 1.67 (1.01,2.76)** f
Infection at baseline (any) 1.56 (0.93,2.59)* f
Antibiotics at baseline (yes) 0.99 (0.60,1.64) f
IV treatment at baseline (yes) 0.95 (0.43,2.07) f
Insertion at hand/posterior wristc 1.67 (1.04,2.70)** 1.66 (1.02,2.69)**
Insertion at forearma 0.58 (0.35,0.97)** e
Insertion at cub. fossa/ant. upper armc 1.01 (0.53,1.93) f
Inserted by IV servicec 0.95 (0.59,1.52) f
Inserted by nursec 2.01 (1.11,3.63)** f
Size (20 g versus 22 g) 1.14 (0.70,1.87) f
Vein quality (poor) 1.26 (0.79,2.01) f
Multiple insertion attempts (yes) 1.32 (0.78,2.23) f
Extension tubing (yes) 1.25 (0.78,1.98) f
3-way tap (yes) 1.33 (0.79,2.24) f
IV treatment at device removal (yes) 2.61 (1.28,5.29)*** e
IV treatment rate at device removald 1.40 (1.07,1.82)** e
IV antibiotics at device removal (yes) 2.07 (1.27,3.38)*** e
IV antibiotics rate at device removald 1.33 (1.09,1.62)*** e
Medication types administered:
- antibioticsc 1.12 (0.67,1.87) f
- cephalosporinsc 0.80 (0.49,1.32) f
- penicillin combinationc 0.75 (0.40,1.41) f
Episode rate (medications and flushes) 1.22 (1.08,1.38)*** 1.25 (1.10,1.41)***
HR hazard ratio, CI confidence interval, IV intravenous
*p value <0.2; **p value <0.05; ***p value <0.01
aModel for the interaction term results included the main effects
bOrdinal: 0 = none/one, 1 = two/three, 2 = four or more
cVersus all others
dPer day, ordinal: 0 = none, 1 = one/two, 2 = three/four, 3 = five or more
eExcluded due to correlation with other covariate
fCovariate not entered into multivariate model (at p ≥ 0.2), or removed during model building at p > 0.05. Only variables p < 0.2 on univariable analysis entered
into the multivariable model
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Limitations
The small pilot sample and single site setting impact on
the interpretation and generalisability of the results. It
was not possible to mask the respective interventions,
and so there was potential for outcome assessment bias.
The use of dedicated research nurses, standardised data
collection and blinded microbiologists minimised the
risk. We did not control flushing volumes used pre- and
post-medications, and this may have confounded the ef-
fect of the randomised flushing. However, analysing the
number of total PIVC accesses per day appears to have
controlled for this factor. The recommended syringe size
for all flushes was a 10 mL syringe; however, we do not
know if this was always used, and excessive pressure
may have been a confounder if smaller sizes were used.
Conclusions and implications
Larger, definitive trials of flushing volume and flushing
frequency of peripheral intravenous catheter manage-
ment are feasible and required. Neither increased flush-
ing volume nor frequency significantly altered the risk of
PIVC failure in this pilot trial; however, the trial had
inadequate power. (Female gender, hand/posterior wrist
placement and frequency of access (flushes and medica-
tion) should be considered confounders in future trials.)
The mechanisms of how IV flushing, medication and
fluid administration impact on the cannula, vessel endo-
thelium and blood components are poorly understood
and require further explication. We need to explore how
syringe technology and method of administration can
make a difference to PIVC outcomes and therefore
transform the delivery and patient experience of IV care.
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